4 Results for "

C42B

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "C42B" in MCE Product Catalog:

Cat. No.: HY-124585
CAS No.: 2222565-19-5
Research Areas:  

Cancer

Y08060 is a selective BET inhibitor. Y08060 inhibits the viability of C4-2B and LNCaP cell lines with IC50 values of 3.23 and 4.41 μM. Y08060 can suppress colony formation as well as AR expression in prostate cancer cell line. Y08060 can be studied in prostate cancer research .
loading...
    loading...
Cat. No.: HY-142772
CAS No.: 2688745-47-1
Y08284 is a potent, selective, oral active CBP bromodomain inhibitor with an IC50 of 4.21 nM. Y08284 suppresses the proliferation of prostate cancer cell lines LNCaP, C4-2B, and 22Rv1. Antitumor activity .
loading...
    loading...
Cat. No.: HY-169349
CAS No.: 6605-17-0
Target:  

Androgen Receptor

Research Areas:  

Cancer

Androgen receptor antagonist 12 (Compound EF2) is an orally active Androgen receptor (AR) antagonist (IC50: 0.30 μM). Androgen receptor antagonist 12 inhibits transcriptional activity of variant AR mutants and and the proliferation of AR-positive PCa cell lines. Androgen receptor antagonist 12 blocks AR nuclear translocation. Androgen receptor antagonist 12 inhibits tumor growth in a C4-2B xenograft mouse model. Androgen receptor antagonist 12 can be used for prostate cancer (PCa) research .
loading...
    loading...
Cat. No.: HY-172170
CAS No.: 3024554-34-2
Target:  

Histone Demethylase

Research Areas:  

Cancer

LSD1-IN-39 (Compound 14) is a reversible inhibitor for LSD1 with an IC50 of 0.18 μM. LSD1-IN-39 exhibits broad-spectrum anti-proliferative activity against cancer cells, inhibits the cell migration of HepG2 and inhibits the epithelial-mesenchymal transition. LSD1-IN-39 exhibits antitumor activity in mouse models .
loading...
    loading...